| Crimi et al15
|
Multicentre RCT |
1,981 |
373 (18.8%) |
BMS vs. DES (PES/EES/ZES) |
1,484 (75%) |
Definite/probable ST |
Composite of MI, stroke, death, and all-cause mortality |
Within CKD population: lowest in ZES (10.6%) compared to EES (14.9%), PES (25.5%), BMS (18.1%), p=0.040. |
Within CKD population: lower in EES and ZES compared to BMS (HR 0.288 and 0.394; p=0.014 and 0.037, respectively) |
Non-significant |
Non-significant |
2 years |
2006-2008 |
| Miao et al7
|
Single-centre prospective |
2,862 |
445 (15.5%) |
DES-related ST in CKD vs. normal renal function |
2,862 (100%) |
Definite/probable ST |
Composite of all-cause mortality, non-fatal MI, TVR |
CKD (10.6%) vs. normal renal function (4.1%); p<0.001. |
Definite/probable ST: CKD (1.8%) vs. normal renal function (0.6%); p=0.014. |
Non-significant |
CKD (7.4%) vs. non-CKD (4.3%); p=0.005 |
1 year |
2008-2009 |
| Tsai et al14
|
Multicentre prospective |
283,593 |
121,446 (42.8%) |
DES vs. BMS |
218,540 (77.1%) |
All-cause mortality, MI, repeat revascularisation, bleeding |
NA |
Lower in DES-treated patients regardless of renal function. |
NA |
Lower in DES-treated patients with normal renal function only. |
Lower in DES-treated patients regardless of renal function, excluding haemodialysis patients. |
2.5 years |
2004-2007 |
| Roberts et al55
|
Single-centre prospective |
4,687 |
1,543 (33%) |
CABG vs. MM CABG vs. BMS CABG vs. DES |
1,278 (27%) |
All-cause mortality |
Composite of death, MI, revascularisation |
CABG vs. MM: superior in CKD, excluding ESRD. CABG vs. BMS: superior in severe CKD CABG vs. DES: no significant differences. ESRD: no significant differences in CABG/BMS/PCI/MM |
NA |
Secondary endpoint lower with CABG vs. BMS/DES/MM except in dialysis patients. |
Secondary endpoint lower with CABG vs. BMS/DES/medical management except in dialysis patients. |
5.1 years |
2003-2010 |
| Lemos et al17
|
Retrospective |
1,080 |
186 (17.2%) |
DES vs. BMS |
537 (49.7%) |
All-cause mortality |
Repeat revascularisation |
All-cause mortality higher in CKD vs. normal renal function regardless of DES or BMS use. DES did not provide additional mortality benefit over BMS in CKD states. |
NA |
Reduced with SES in both CKD and normal renal function. |
NA |
1 year |
2001-2002 |
| Wanha et al18
|
Retrospective |
1,908 |
331 (17.3%) |
DES-I (PES, SES) vs. DES-II (EES, ZES, BES) |
1,908 (100%) |
DES efficacy: MACCE (MI, TVR, death, stroke) DES safety: ST |
NA |
No improvement with DES-II over DES-I irrespective of renal function. |
No difference between CKD vs. normal renal function. |
No improvement with DES-II |
No improvement with DES-II |
1 year |
2009-2010 |
| Cooper et al35
|
Retrospective |
483,914 |
379,034 (78.3%) |
CABG |
NA |
All-cause mortality (within 30 days of CABG) |
Stroke, repeat CABG |
Operative mortality rose inversely with decline in renal function. |
NA |
Repeat CABG rose inversely with decline in renal function |
NA |
NA |
2000-2003 |
| BES: biolimus-eluting stent; BMS: bare metal stent; CABG: coronary artery bypass grafting; CKD: chronic kidney disease; DES: drug-eluting stent; DES-I: first-generation DES; DES-II: second-generation DES; EES: everolimus-eluting stent; eGFR: estimated glomerular filtration rate; ESRD: end-stage renal disease; HR: hazard ratio; MACCE: major adverse cardiac and cerebral events; MI: myocardial infarction; MM: medical management; NA: not applicable; PES: paclitaxel-eluting stent; RCT: randomised controlled trial; SES: sirolimus-eluting stent; ST: stent thrombosis; TVR: target vessel revascularisation; ZES: zotarolimus-eluting stent |
